Large Molecules Drug Substance CDMO Market

Large Molecules Drug Substance CDMO Market Analysis

The Large Molecules Drug Substance CDMO Market size is estimated at USD 12.10 million in 2025, and is expected to reach USD 18.28 million by 2030, at a CAGR of 8.6% during the forecast period (2025-2030).

The market is driven by the increasing approval of molecules for drugs, the rising incidence of chronic and infectious diseases, the growing demand for biologics and biosimilars, and the increasing R&D investment by pharmaceutical companies for large molecules.

The increasing investment for the facility expansion that provides the large molecules of drug substance CDMO services is expected to boost the market during the forecast period. For instance, in January 2022, Alcami, a CDMO, reported a USD 10 million investment to expand its laboratory operation in Durham, North Carolina. The investment sought to expand the laboratory by over 6700 ft², incorporating state-of-the-art equipment. It aimed to bolster extensive molecule characterization capabilities for biologics at various development stages. The facility would support both parenteral manufacturing projects and independent analytical clients.

Moreover, strategic activities by the market players, such as mergers and acquisitions and partnership and services expansion, are expected to contribute to the market during the forecast period. For instance, in May 2023, Aurigene Pharmaceutical Services Limited, a subsidiary of Dr. Reddy's Laboratories, reported the construction of a new and advanced facility that will be used to develop and manufacture therapeutic proteins, antibodies, and viral vectors. This facility will be complemented by exclusive access to a large-scale GMP manufacturing facility with a drug substance capacity of 15,000 liters and fill-finish capabilities, allowing for seamless production of commercial quantities.

In September 2022, FUJIFILM Diosynth embarked on an expansion of its sizable microbial manufacturing facility in Billingham, the United Kingdom. The project, spanning an area of 1858 square meters (20,000 sq. ft), will cater to the increasing need for microbial development and production.

Hence, all the above factors mentioned, such as increasing investment for the production of large molecules of drug substances and strategic initiatives taken by the market players, are anticipated to grow the market during the forecast period. However, compliance issues while outsourcing and changing scenarios within developing countries are expected to restrain the market's growth during the forecast period.

Large Molecules Drug Substance CDMO Market Trends

The Cell Line Development Segment is Expected to Hold a Significant Share During the Forecast Period

Cell line development for large molecules of drug substance involves creating and optimizing host cell lines that can express and produce the desired therapeutic proteins, such as monoclonal antibodies or other biologics. CDMOs specializing in cell line development may be engaged to provide expertise, infrastructure, and resources for efficient and effective large-molecule drug substance production. The company aims to establish a robust and reproducible cell line capable of producing the therapeutic protein at the required scale and quality for clinical and commercial use.

Cell line development requires specialized knowledge and skills in molecular biology, genetics, and bioprocessing. CDMOs with expertise in these areas can offer valuable insights and capabilities, attracting companies looking to outsource this complex aspect of drug development. In addition, CDMOs offer scalability in cell line development and subsequent bioprocessing. They have the infrastructure to scale production to meet increasing demands, providing flexibility for pharmaceutical companies without requiring substantial capital investments.

Moreover, market players' strategic activities are expected to boost the segment during the forecast period. For instance, in November 2022, Abzena invested USD 20 million to expand biologics drug substance capacity to 2000L scale, extra cell line development, and chemistry laboratory space in a new GMP facility. Additionally, in November 2023, Lonza announced the launch of its new GS Effex cell line to develop therapeutic antibodies with enhanced potency.

Similarly, in April 2023, Lotte Biologics and Excellence entered a collaboration agreement to join forces in the biopharmaceutical CDMO market. The partnership aims to offer comprehensive CDMO services encompassing pharmaceutical cell line development and large-scale manufacturing. In addition, AGC Biologics, a prominent CDMO, has garnered recognition from Acquisition International as a 2022 Leading Innovator in Mammalian Cell Line Development for the United States of America.

Hence, the benefits offered by the CDMO for cell line development and market players' strategic activities are expected to boost segment growth during the forecast period.

North America is Expected to Hold a Significant Market Share During the Forecast Period

North America is expected to hold a significant share owing to increasing extensive molecule drug approvals by the USFDA, rising incidence of infectious diseases, high demand for novel therapeutics, and higher capital investments by pharma and biotech firms in advanced technologies for establishing partnerships with CDMOs are the key factors driving the market.

The increasing investment in R&D and approval of biologics products are expected to boost the market during the forecast period. For instance, the Pharmaceutical Research and Manufacturers of America reported in 2023 that American pharmaceutical companies spent USD 238 billion on R&D in 2022. Thus, the need for innovative treatments and therapies for chronic diseases drives extensive research and development activities. Large molecule contract manufacturers support these efforts by providing high-quality, reliable products for treating chronic diseases, likely boosting the market during the forecast period.

Many players, such as Catalent, Cambrex Corporation, LabCorp Drug Development, and Fujifilm Diosynth Biotechnologies, drive the market. For instance, in April 2022, Catalent announced a multi-year investment worth USD 350 million at its Bloomington, Indiana, facility to broaden large molecule drug product and drug substance manufacturing capabilities. Key players employed mergers, acquisitions, partnerships, and facility expansions to sustain their market dominance. For instance, in November 2023, FUJIFILM Diosynth Biotechnologies, a CDMO, hosted a site unveiling celebration for its USD 2 billion large-scale cell culture manufacturing facility in Holly Springs. The site will provide drug substance manufacturing, automated fill-finish and assembly, packaging, and labeling services for global biopharmaceutical customers.

Increased R&D investments and strategic initiatives from market participants are anticipated to propel market expansion throughout the forecast period, resulting in a boost to the market.

Large Molecules Drug Substance CDMO Industry Overview

The large molecule drugs substance market is moderately competitive due to the presence of several companies operating globally as well as regionally. The companies are focused on expanding the facilities for large molecules drug substance. Some major market players are Thermo Fisher Scientific Inc., Eurofins Scientific, Wuxi Biologics, Samsung Biologics, and Catalent Inc.

Large Molecules Drug Substance CDMO Market Leaders

Large Molecules Drug Substance CDMO Market News

• February 2024: Eurofins CDMO Alphora established a state-of-the-art pilot-scale biologics development facility. Eurofins CDMO Alphora Inc. successfully combined its expertise in API and HPAPI with comprehensive biologics capabilities through the completion of its biologics pilot scale facility.
• September 2023: Samsung Biologics reported a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.